Snapshot from Apr 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / WuXi Biologics
Company

WuXi Biologics

Tracked across 2 events · 15 articles · First seen Feb 03, 2026 · Last active Mar 03, 2026

Sentiment
15
Attention
2
Events
2
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
2 50
Business
WuXi Biologics, Vertex Pharmaceuticals TCE Agreement
WuXi Biologics signed a license and research service agreement with Vertex Pharmaceuticals Incorporated, granting Vertex exclusive global rights to develop and commercialize a trispecific T-cell Engager (TCE). WuXi Biologics will receive an upfront payment, milestone payments, and royalty payments, enhancing its revenue streams and validating its CRDMO model.
Feb 03, 2026 · 7 articles
2 -20
Business
Hong Kong Market Volatility Amid Global Mixed Signals
WuXi Biologics' stock has tumbled or cratered, indicating significant losses.
Feb 25, 2026 · 8 articles
Relationships (2)
Vertex Pharmaceuticals partner ↔ WuXi Biologics WuXi Biologics and Vertex Pharmaceuticals Incorporated entered a licensing and r
Chris Chen CEO ↔ WuXi Biologics Chris Chen is the CEO of WuXi Biologics.
NEWSDESK
Track WuXi Biologics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.